SABS SAB Biotherapeutics, Inc.
$3.41▼ -0.29%
Healthcare
Other
After hours
$3.50▲ +2.64%
Sep 11, 7:30 PM ET
Volume 712.0K
Avg Volume (10D) 259.1K
Key Metrics & Fundamentals
Market Cap
$310.26M
P/E Ratio
14.2
Div Yield
–%
52W Range
1.85 - 5.15
% vs 50 MA
-7.89%
% vs 200 MA
-10.56%
RSI-14
35.0
MACD Histogram
-0.0400
Beta (1Y vs SPY)
1.31
Free Cash Flow
-$11.43M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$20.48M
COGS
–
Operating Exp
$23.38M
Operating Income
-$23.38M
EBIT
-$23.38M
Pretax Income
-$22.49M
Net Income
-$22.49M
EPS (Diluted)
-0.28
Price & Volume History
Loading chart…
Recent News
SAB BIO to Participate in Upcoming Investor Conferences
GlobeNewswire · Sep 1, 2026 12:30 PM
SAB Biotherapeutics Q2 Earnings Call Highlights
MarketBeat · Aug 7, 2026 12:03 PM
SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ...
GuruFocus.com · Aug 6, 2026 11:14 PM
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
GlobeNewswire · Aug 6, 2026 11:30 AM
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
GlobeNewswire · Jul 30, 2026 12:30 PM
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment
Insider Monkey · Jul 15, 2026 3:43 PM
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
GlobeNewswire · Jul 7, 2026 12:00 PM
Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?
Insider Monkey · Jul 5, 2026 10:08 PM
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS)
Insider Monkey · Jun 30, 2026 4:34 PM
Barclays Initiates SAB Biotherapeutics at Overweight With $13 Price Target
MT Newswires · Jun 24, 2026 11:37 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See SABS's money flow as a full page
Social Sentiment
No Reddit posts found for SABS.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.